Ceftriaxone-Induced Immune Hemolytic Anemia: In Vitro Reversal with Peptide Inhibitor of Complement C1 (PIC1)
We report a case of ceftriaxone-induced immune hemolytic anemia in a 10-year-old with chronic active Epstein–Barr virus disease and hemophagocytic lymphohistiocytosis. After chemotherapy, she became febrile and received ceftriaxone. She rapidly developed respiratory failure and anemia. Her direct an...
Saved in:
Main Authors: | Kenji M. Cunnion, Lisa M. Feagin, Michael F. Chicella, Cortney L. Kaszowski, Pamela S. Hair, Jessica Price, William C. Owen |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-01-01
|
Series: | Case Reports in Hematology |
Online Access: | http://dx.doi.org/10.1155/2019/4105653 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Unraveling the complexity: Case reports of drug-induced hemolytic anemia due to ceftriaxone
by: Anshika Yadav, et al.
Published: (2024-12-01) -
Ceftriaxone-induced hemolytic anemia managed successfully in a 54-year-old woman: a case report and literature review
by: Liqian Zhang, et al.
Published: (2025-01-01) -
Hyperglycemia Inhibits Complement-Mediated Immunological Control of S. aureus in a Rat Model of Peritonitis
by: Clifford T. Mauriello, et al.
Published: (2014-01-01) -
Prediction of hemolytic peptides and their hemolytic concentration
by: Anand Singh Rathore, et al.
Published: (2025-02-01) -
Immunotherapy-associated autoimmune hemolytic anemia
by: Uqba Khan, et al.
Published: (2017-02-01)